Major

Vitamin C-500 mg

Serving
1 Capsule(s)
Form
capsule-unknown
UPC
309046404606
DSLD
Formula hash
a049211d749f
Brand context
Catalog
191
products
With avoid flag
94
products
FDA recalls
0
history
CAERS
3
reports
Avoid-flaggedObjective label signals
Flagged excipients
5
1 avoid · 4 caution
FDA recalls
0
no recall history
CAERS reports
2
FDA consumer events
Certifications
0
none recorded
1 avoid-level excipient · Every flag below links to the authority's published citation.

Supplement Facts

1 active ingredients
IngredientAmount% DV
Vitamin C
vitaminUNII · PQ6CK8PD0R
UL · set5 effects
500 mg833%
What this product supports · authorized claims

5 authority-backed effects

Rolled up from EFSA / FDA / NIH ODS authorized function claims on this product's active ingredients. Each row shows which ingredients contribute.

Flagged excipients

5 flagged · authority citations

  • ● AVOIDTitanium Dioxide
    color

    Banned in EU food products effective 2022-08 (Commission Regulation (EU) 2022/63) following EFSA Panel opinion that a safe daily intake could not be established due to genotoxicity concerns. Still GRAS in the US under 21 CFR 73.575 but EU position is stricter.

  • ◐ CAUTIONFD&C Yellow #6 Lake
    color

    EU requires 'attention in children' warning per Reg 1333/2008 Annex III (Southampton study 2007). Banned in Norway + Finland; allowed in US under 21 CFR 74.706 with declaration.

  • ◐ CAUTIONFD&C Blue #1 Lake
    color

    EU requires 'attention in children' warning per Commission Regulation 1333/2008 Annex III. Limited to specific food categories; capsule-shell use permitted with restrictions.

  • ◐ CAUTIONFD&C Red #3 Lake
    color

    FDA revoked food/ingested-drug color additive approval for FD&C Red 3 in January 2025 (Docket FDA-2022-C-2886). Manufacturers have until January 2027 (foods) / January 2028 (ingested drugs) to reformulate.

  • ◐ CAUTIONFD&C Yellow #5 Lake
    color

    EU requires warning label 'may have an adverse effect on activity and attention in children' per Commission Regulation 1333/2008 Annex III (following Southampton study 2007). FDA requires specific label declaration (21 CFR 74.705).

FDA CAERS · adverse event context
2
consumer-submitted adverse event reports filed with the FDA CFSAN Adverse Event Reporting System mentioning this product or its brand.

CAERS reports are unverified consumer submissions — not adjudicated causality. Large well-known brands accumulate proportionally more reports simply due to broader use. About CAERS →

Other ingredients

Gelatin · Sugar · Pharmaceutical Glaze · Magnesium Silicate · Polyvinylpyrrolidone

Chemically equivalent

Same formula, different brand

Products with identical sorted (ingredient, amount) tuples.